Human endothelial colony forming cells (ECFCs) require endothelial protein C receptor (EPCR) for cell cycle progression and angiogenic activity

Figures

• 

  Fig. 1. ECFCs show widespread expression of EPCR on cell surface. a Cell surface expression by flow cytometry of EPCR (pink histogram), CD157 (orange histogram), and CD34 (blue histogram) relative to unstained sample (grey histogram). Violin plots show distribution of (b) % Expression and (c) MFI (median fluorescence intensity) for EPCR, CD157, and CD34, n = 9. d Immunofluorescence of EPCR (AF488) in green shows widespread distribution on cell surface. Nucleus stained with DAPI in blue. Scale bar 50 µm. One-way ANOVA was performed, ns = not significant, **p < 0.01; ***p < 0.001, ****p < 0.0001. e Procr average expression by cell type from a model of severe acute lung injury GSE211335. f Procr percentage expression across lung cell types and timepoints after injury g Spearman correlation of Procr transcript with reported markers of endothelial stemness and differentiation

• 

  Fig. 2. Expression of EPCR in ECFCs is essential for endothelial functionality. a PROCR silencing by PROCR siRNA confirmed in Western blot. Quantification of protein levels showed significant reduction in EPCR expression (49 kDa) relative to β-actin (42 kDa) in PROCR siRNA group compared to control untransfected and control siRNA groups, n = 4. Endothelial cell functional assays performed comparing control untransfected, control siRNA, and PROCR siRNA groups to include: b clonogenics assay and quantification of % colony area, n = 5, c tubulogenesis assay and quantification of % tube area, n = 6, d scratch migration assay from 0 to 6 h and quantification of distance migrated, n = 4, e barrier formation and quantification of cell index at 2.28 h and 12 h, n = 3 and f normalized cell index after thrombin treatment and quantification, n = 3. In all assays, control siRNA and PROCR siRNA groups are normalized to control untransfected, which is represented by the black dashed line, and analyzed by paired t-test. *p < 0.05, **p < 0.01; ***p < 0.001

• 

  Fig. 3. ECFCs with knocked-down EPCR by PROCR siRNA exhibited a negative enrichment for cell cycle gene signature. Bulk RNA-seq of 6 biological replicates highlighted 1,101 differentially expressed genes presented in (a) MA plot of PROCR siRNA vs control siRNA, n = 6. KEGG pathway analysis revealed that among the most down regulated gene signatures was CELL_CYCLE (b), and among the most up regulated was TGF_BETA_SIGNALING_PATHWAY (c). Heatmap showing cell cycle associated genes significantly downregulated (d) and upregulated (e) in PROCR siRNA compared to control siRNA

• 

  Fig. 4. Knocking down PROCR in ECFCs halted the cell cycle in G1 phase. a Immunofluorescence staining of Ki67 (AF488 in green) in PROCR siRNA group vs control untransfected and control siRNA, nucleus stained with DAPI (blue), scale bar 50 µm. Violin plots show % ki67 positive nuclei quantified, n = 3 biological replicates, each technical replicate has been plotted. b PROCR silencing leads to decrease in PCNA (30 kDa) expression in western blot, relative to β-actin (42 kDa); quantification shows significant decrease in PCNA expression in PROCR siRNA group compared to control untransfected and control siRNA groups, n = 4. Control untransfected, control siRNA, and PROCR siRNA groups were assessed by flow cytometry and % expression quantified (in all plots grey histogram represents unstained control). c EPCR expression (pink histogram) and quantification, n = 6, d 7AAD expression (blue histogram) and quantification, n = 3. e EdU cell proliferation assay (purple histogram) and quantification, n = 5. f Cell cycle analysis using Vybrant dye cycle by flow cytometry (green histogram) shows distribution of G0/G1 (1st peak) and G2/M (2nd peak) phases of cell cycle. g Quantification of % cells…

• 

  Fig. 5. Diminished EPCR expression led to increased pSMAD2/3 and pERK via TGFβ2 signaling pathway as shown by Western blot (a) and densitometry quantification for pSMAD2/3 (b), pERK (c), Transgelin (d), and pFAK (e). f TGFβ2 secretion from control siRNA and PROCR siRNA assessed by ELISA. g Evaluation of TGFβ2 release when PROCR siRNA ECFCs were treated with Alk5 inhibitor SB525334. All data analyzed using a ratio paired t test, n = 4, *p < 0.05, **p < 0.01

• 

  Fig. 6. PROCR mRNA expression levels are associated with proliferative status in ECFCs a Expression of PROCR in scRNAseq of quiescent vs proliferating ECFCs. PROCR expression sub-divided by cell cycle phases using gene signatures, G1 (blue), G2M (yellow), S (red). b Cell cycle distribution by flow cytometry confirms quiescent ECFC monolayers (red histogram) are arrested in G1 phase and have loss of G2M peak compared to proliferating ECFCs (blue histogram). EPCR expression is presented as median fluorescence intensity (MFI). Grey histograms represent unstained control. Quantification of EPCR MFI and % expression analyzed by paired t-test, n = 4, *p < 0.05, **p < 0.01. c Contour plot shows gating strategy for EPCRlow, EPCRmid, and EPCRhigh populations which were sorted (by FACS) and plated for d clonogenic assay. e Violin plots show quantification of total number of colonies, as well as % high proliferative potential (HPP) and % low proliferative potential (LPP). Data analyzed by one-way ANOVA, ns = not significant, **p < 0.01, *** p < 0.001, ****p < 0.0001, n = 3 biological replicates, each technical replicate has been plotted. f Sorted populations of EPCRlow, EPCRmid, and EPCR.high were…